PMID- 26446512
OWN - NLM
STAT- MEDLINE
DCOM- 20161031
LR  - 20161230
IS  - 2047-2927 (Electronic)
IS  - 2047-2919 (Linking)
VI  - 3
IP  - 6
DP  - 2015 Nov
TI  - Effects of silodosin on sexual function - realistic picture from the everyday 
      clinical practice.
PG  - 1076-81
LID - 10.1111/andr.12095 [doi]
AB  - The treatment with alpha1-blockers in patients complaining of lower urinary tract 
      symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) is associated with 
      potential adverse events (AEs), thus including ejaculatory dysfunction (EjD). We 
      sought to assess the effects of a 3-month course of silodosin 8 mg daily dosing 
      on sexual functioning, mainly including ejaculation and orgasm, in a cohort of 
      100 consecutive sexually active men in the real-life setting. Patients completed 
      the International Index of Erectile Function-Orgasmic Function (IIEF-OF) domain 
      and the International Prostate Symptom Score (IPSS) both at baseline and at 
      survey. Likewise, patients completed a 16-item self-administered questionnaire 
      with closed questions also including specific questions regarding 
      treatment-related adverse events on sexual functioning. Rates and predictors of 
      OF impairment and drug discontinuation were investigated. At survey, silodosin 
      resulted highly effective in improving IPSS-total and subscales (all p < 0.01). 
      Anejaculation, hypospermia, reduced or absent orgasmic feeling, low sexual desire 
      and erectile dysfunction were subjectively reported by 48 (48%), 23 (23%), 11 
      (11%), 6 (6%), 7 (7%) and 11 (11%) patients respectively. Overall, a reduction in 
      IIEF-OF domain score was observed in 64 (64%) patients. Patients with decreased 
      IIEF-Q9 and/or IIEF-Q10 scores were significantly younger than those without any 
      decrease (p = 0.02). Of all, only 7% of the patients discontinued silodosin 
      because of anejaculation. Silodosin confirms to be highly effective in patients 
      with LUTS/BPH; of them, almost 70% report either anejaculation or hypospermia, 
      with a concomitant OF impairment in 17% of the patients. Younger patients showed 
      higher rates of a concomitant impairment of ejaculation and OF. Overall, 
      anejaculation caused drug discontinuation in 7% of the patients.
CI  - (c) 2015 American Society of Andrology and European Academy of Andrology.
FAU - Capogrosso, P
AU  - Capogrosso P
AD  - Universita Vita-Salute San Raffaele, Milan, Italy.
AD  - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San 
      Raffaele, Milan, Italy.
FAU - Serino, A
AU  - Serino A
AD  - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San 
      Raffaele, Milan, Italy.
FAU - Ventimiglia, E
AU  - Ventimiglia E
AD  - Universita Vita-Salute San Raffaele, Milan, Italy.
AD  - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San 
      Raffaele, Milan, Italy.
FAU - Boeri, L
AU  - Boeri L
AD  - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San 
      Raffaele, Milan, Italy.
FAU - Deho, F
AU  - Deho F
AD  - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San 
      Raffaele, Milan, Italy.
FAU - Damiano, R
AU  - Damiano R
AD  - Research Doctorate Program in Urology, Magna Graecia University, Catanzaro, 
      Italy.
FAU - Briganti, A
AU  - Briganti A
AD  - Universita Vita-Salute San Raffaele, Milan, Italy.
AD  - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San 
      Raffaele, Milan, Italy.
AD  - Research Doctorate Program in Urology, Magna Graecia University, Catanzaro, 
      Italy.
FAU - Montorsi, F
AU  - Montorsi F
AD  - Universita Vita-Salute San Raffaele, Milan, Italy.
AD  - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San 
      Raffaele, Milan, Italy.
FAU - Salonia, A
AU  - Salonia A
AD  - Universita Vita-Salute San Raffaele, Milan, Italy.
AD  - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San 
      Raffaele, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20151007
PL  - England
TA  - Andrology
JT  - Andrology
JID - 101585129
RN  - 0 (Adrenergic alpha-1 Receptor Antagonists)
RN  - 0 (Indoles)
RN  - 0 (Urological Agents)
RN  - CUZ39LUY82 (silodosin)
SB  - IM
MH  - Adrenergic alpha-1 Receptor Antagonists/*adverse effects
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Ejaculation/drug effects
MH  - Humans
MH  - Indoles/*adverse effects
MH  - Lower Urinary Tract Symptoms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Oligospermia/chemically induced/physiopathology
MH  - Prevalence
MH  - Prostatic Hyperplasia/*drug therapy
MH  - Risk Factors
MH  - Sexual Behavior/*drug effects
MH  - Sexual Dysfunction, Physiological/*chemically 
      induced/diagnosis/physiopathology/psychology
MH  - Spermatogenesis/drug effects
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
MH  - Urological Agents/*adverse effects/therapeutic use
OTO - NOTNLM
OT  - benign prostatic hyperplasia
OT  - ejaculatory dysfunction
OT  - sexual dysfunction
OT  - silodosin
EDAT- 2015/10/09 06:00
MHDA- 2016/11/01 06:00
CRDT- 2015/10/09 06:00
PHST- 2015/05/30 00:00 [received]
PHST- 2015/07/02 00:00 [revised]
PHST- 2015/07/14 00:00 [accepted]
PHST- 2015/10/09 06:00 [entrez]
PHST- 2015/10/09 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - 10.1111/andr.12095 [doi]
PST - ppublish
SO  - Andrology. 2015 Nov;3(6):1076-81. doi: 10.1111/andr.12095. Epub 2015 Oct 7.